Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a bee imageApril 17 2018

A manufacturing delay is causing problems around availability of Epipen (Senior) 0.3mg Adrenaline Auto-Injector. 

Mylan, parent company of MEDA Pharmaceuticals, the UK Market authorisation holder, says supply problems will be intermittent, with the next shipment expected to be delivered to its UK distribution partner at the end of April. In the meantime, EpiPen 0.3mg Adrenaline Auto-Injectors may not be available, although supplies of the EpiPen Jr 0.15mg Adrenaline Auto-Injectors are not currently affected.

EpiPen is manufactured by Meridian Medical Technologies, a Pfizer company. 

“Mylan is working closely with Pfizer to manage supply carefully to avoid long-term supply shortages. Pfizer anticipates that production rates will increase over the coming months; however, at this time, cannot commit to a specific time for when the supply constraint will be fully resolved,” a notice on the EpiPen website said.

“We are confident in the safety and efficacy of the EpiPen products being produced at Pfizer’s site and are working closely with them to alleviate the situation and achieve a steady state of supply as expeditiously as possible.”

Mylan has not been able to any specific treatment recommendation to individual patients but does recommend that patients speak to their healthcare provider for appropriate actions to be taken.

The website points out that the expiry date of products is at on the last day of the indicated month, Further information is available from Mylan on 01707 853100.

EpiPen website 

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...